For research use only. Not for therapeutic Use.
EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants[1].
EMI56 inhibits EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. EMI56 can be used in the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC)[1].
EMI56 (10, 15, 20 μM; 2 h of treatment) strongly inhibits total EGFR levels, activation and downstream signaling in PC9 EGFR ex19del/T790M/C797S cells[1].
| Catalog Number | I015150 |
| CAS Number | 2414374-41-5 |
| Synonyms | 3-(1,3-benzoxazol-2-yl)-7-(diethylamino)-6-methylchromen-2-one |
| Molecular Formula | C21H20N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H20N2O3/c1-4-23(5-2)17-12-19-14(10-13(17)3)11-15(21(24)26-19)20-22-16-8-6-7-9-18(16)25-20/h6-12H,4-5H2,1-3H3 |
| InChIKey | OYQNORRYAWXDHW-UHFFFAOYSA-N |
| SMILES | CCN(CC)C1=CC2=C(C=C1C)C=C(C(=O)O2)C3=NC4=CC=CC=C4O3 |
| Reference | [1]. Punit Saraon, et al. A Drug Discovery Platform to Identify Compounds That Inhibit EGFR Triple Mutants.Nat Chem Biol. 2020 May;16(5):577-586. |
